TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03698994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Given PO
Study: NCT06624033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amino acids kinetics
Description: After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: amino acids kinetics
Description: After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amino acids kinetics
Description: After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: amino acids kinetics
Description: After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: amino acids kinetics
Description: After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amino acids kinetics
Description: After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured.
Study: NCT00336024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC resuce

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC resuce

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC
Study: NCT04361513

Intervention type: DRUG
Group type: OTHER
Intervention: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)
Description: intra-articular injection of triamcinilone
Study: NCT03870178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.
Study: NCT01764373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
Study: NCT00977405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collatamp Gentamicin Implant
Description: Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
Study: NCT02780986

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Female entertainment worker intervention group
Description: The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heterosexual men intervention group
Description: This will be delivered via 3 main activities:~1. Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~2. Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~3. Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants
Study: NCT01539863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maintenance care
Description: Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as needed
Description: Participants may never receive treatment, there is no upper limit
Study: NCT00336024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02405169

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4 vs 6 implant treatment in the maxilla

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 vs 6 implant treatment in the maxilla
Study: NCT03875092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion Carboplatin dose should not exceed 900 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Carboplatin dose should not exceed 900 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline placebo for pembrolizumab
Description: IV infusion
Study: NCT01787487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study: NCT03698838

Intervention type: DEVICE
Intervention: McDESPOT
Description: MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
Study: NCT03045276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Feedback and Economic Incentives: Arm 1
Description: The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Feedback and Economic Incentives: Arm 2
Description: The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal.
Study: NCT02892604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump to inControl AP platform
Description: Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.
Study: NCT01118624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push administration over 3-5 minutes.~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1.0-1.25 mg orally~Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate.
Study: NCT00564837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program
Description: Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy-supervised rehabilitation program
Description: Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
Study: NCT00978939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Drainage Instructions
Description: Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aggressive Drainage Instructions
Description: Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
Study: NCT03110861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement
Description: Pulsta® Transcatheter Pulmonary Valve Replacement
Study: NCT02625441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420 mg i.v. 3-weekly for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
Study: NCT03820817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Given PO
Study: NCT02046083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arachid
Study: NCT03861312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neck Laterality
Description: Patients who belonged to the neck group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot Laterality
Description: Patients who belonged to the foot group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program
Study: NCT01176695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fish oil containing lipid emulsion
Description: medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCT/LCT containing lipid emulsion
Description: medium chain triglycerides, long chain triglycerides
Study: NCT01862939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: 1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: 1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match part 2 DS-7309
Study: NCT00826592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
Study: NCT02744664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: After entering the group subject receive Cryotherapy on lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: After Cryotherapy, subjects begin Icotinib administration
Study: NCT02417922

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACP
Description: 4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
Study: NCT01539551

Intervention type: OTHER
Intervention: check BNP and lactate
Description: we will collect patients's blood samples on Day 0, Day1 and Day2
Study: NCT03781232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.3
Description: Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.3
Description: Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
Study: NCT01541618

Intervention type: OTHER
Intervention: MSDX Complex-1 Biomarker test
Description: MSDX Complex-1 Biomarker test
Study: NCT01528644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alginate beads containing ferrous gluconate
Description: After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous gluconate in a capsule
Description: After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous gluconate in a capsule in presence of calcium
Description: After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alginate beads with ferrous gluconate in presence of calcium
Description: After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
Study: NCT03953729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start.
Study: NCT01488864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Description: AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.~During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.~The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation.
Study: NCT03410082

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titration under the guidance of BIS
Description: The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if BIS is greater than 80; The infusion rate is decreased by 0.1mcg/kg/h if BIS is less than 60.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Titration under the guidance of OAA/S
Description: The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if OAA/S is greater than 3; The infusion rate is decreased by 0.1mcg/kg/h if OAA/S is less than 3.